LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News NEWS FLASH L impact Sep 29, 2026, 09:11 PM UTC

Brazil's Brava Energia says it started production at well PPT-52

Brava Energia S.A. BMFBOVESPA:BRAV3

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

BRAV3

Related stories

Brazil's GPA gets Susep greenlight for in-house insurance brokerage Companhia Brasileira de Distribuicao SA BMFBOVESPA:PCAR3 L impact | NEWS | Sep 29, 2026, 10:10 PM UTC Zealand Pharma A/S (ZEAL) Publishes Phase 2 Petrelintide Data; To Present at EASD Zealand Pharma A/S said Phase 2 ZUPREME-1 results for petrelintide were published in The Lancet Diabetes & Endocrinology and will be presented at EASD 2026 on Sept. 30 at 3:30pm CE L impact | NEWS | Sep 29, 2026, 10:08 PM UTC BetterLife Pharma Inc. (BETR) Adds NASDAQ-Related Votes, Moves AGM to Dec. 9 BetterLife Pharma rescheduled its AGM to Dec. 9, 2026 and reclassified it as an AGSM to include special items required to meet NASDAQ listing qualifications.Material DetailsContext L impact | NEWS | Sep 29, 2026, 10:08 PM UTC Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology Press release — No. 18 / 2026Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The L impact | NEWS | Sep 29, 2026, 10:08 PM UTC Japan, US And Europe To Agree Steel Monitoring Framework - Yomiuri L impact | NEWS | Sep 29, 2026, 10:07 PM UTC Eli Lilly: Retatrutide Reduced A1C By Up To 1.6 Percentage Points Versus Placebo L impact | NEWS | Sep 29, 2026, 10:06 PM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.